Abstract:diagnosis of PTSD. Finally, I will discuss aspects of the various trials that point to how NAC may be most effectively employed clinically in combination with psychosocial interventions, and perhaps other pharmacological treatments. Abstract There has been a decline in new therapies for unipolar depression. Current pharmacological therapies are attributed to symptom remission in only 30% of individuals with unipolar depression. As such, there is a clear need for the development of new therapies, instigated by investigators rather than reliance on pharmaceutical companies. There have been significant advancements in the understanding of the underlying pathophysiology of unipolar depression. Significant evidence is available to suggest that unipolar depression is mediated by inflammation. This is demonstrated by the induction of depressive symptoms fol-lowing pro-inflammatory treatment (e.g. interferon in hep-atitis-C) and more importantly, by alterations in peripheral cytokine levels in individuals with unipolar depression. Given this, we planned to trial a treatment specifically targeting inflammation as an adjunct to usual for individuals with mod-erate-severe unipolar depression. The agent selected is minocycline, a tetracycline antibiotic which has also been shown to inhibit microglial activation and also reduce oxidative stress, augment glutamate pathways and promote neuronal growth. This agent is of particular interest as in addition to increased inflammation, depression is also characterized by increased oxidative stress, altered glutamate function and decreased levels of neuronal growth factors (e.g. BDNF). We have completed a pilot double-blind placebo controlled trial of 200 mg/ day of minocycline as an adjunct to treatment as usual. The study includes 12 weeks of treatment followed by a follow-up visit 4 weeks later. The primary outcome measure for the study is the Montgomery Asberg Depression Rating Scale and a variety of clinical impression, functioning and quality of life scales are also included as secondary outcomes. The last study visit will be completed in December 2015 and trial results will be available in early 2016 to determine the preliminary efficacy of minocycline as an adjunctive therapy for moderate to severe unipolar depression. Abstract With depressive disorders the leading source of disability glob-ally, the identification of new targets for prevention and man-agement is imperative. A rapidly emerging field of research suggests that the microbiome-brain axis is of substantial rel-evance to mood and behavior. Similarly, unhealthy diet has recently emerged as a significant correlate of and risk factor for depression. This review provides evidence for the gut microbiota as a key factor mediating the link between diet and depressive illness and focuses on the potential of gut-focused interventions for the prevention and treatment of mood disorders. Recent findings: The development of new technologies is afford-ing a better understanding of how diet influences gut microbiota composition and activity and how this may, in turn, influence depressive illness. New evidence is also pointing to the possible utility of pre and probiotic formulations and fermented food in influencing mental health. Summary: Although in its early stages, the emerging field of research focused on the human microbiome suggests an impor-tant role for the gut microbiota in influencing brain development, behavior and mood in humans. The recognition that the gut microbiota interacts bi-directionally with other environmen-tal risk factors, such as diet and stress, suggests promise in the development of interventions targeting the gut microbiota for the prevention and treatment of common mental health disorders. Abstract Introduction: Depression in bipolar disorder is complex to treat, with few efficacious agents. Bipolar disorder thus is a significant burden on individuals, caregivers and the broader community. Current treatments are generally more effective against manic than depressive symptoms. The current study capitalises on recent evidence that alterations in mitochondrial function occur in bipolar disorder. Since there are many agents that have actions on mitochondrial bioenergetics, that this may be a druggable target. Methods: This was a 3 arm 16-week study which aimed to explore the potential effects of placebo,

Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial

Effects of low-dose aspirin in bipolar disorder: study protocol for a randomised controlled trial (the A-Bipolar RCT)

Exploring Clinical Subgroups of Participants with Major Depressive Disorder that may Benefit from Adjunctive Minocycline Treatment

Protocol and Rationale-The Efficacy of Minocycline As an Adjunctive Treatment for Major Depressive Disorder: A Double Blind, Randomised, Placebo Controlled Trial

Minocycline As an Adjunctive Therapy for Unipolar Depression

Exploring interleukin-6, lipopolysaccharide-binding protein and brain-derived neurotrophic factor following 12 weeks of adjunctive minocycline treatment for depression

Efficacy of inflammation-based stratification for add-on celecoxib or minocycline in major depressive disorder: Protocol of the INSTA-MD double-blind placebo-controlled randomised clinical trial

Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial

Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial

Adjunctive Minocycline for Major Depressive Disorder: A Sub-Study Exploring Peripheral Immune-Inflammatory Markers and Associated Treatment Response

Minocycline As Adjunctive Treatment for Major Depressive Disorder: Pooled Data from Two Randomized Controlled Trials.

Effect of Minocycline on Depressive Symptoms in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial

Efficacy and tolerability of minocycline in depressive patients with or without treatment-resistant: a meta-analysis of randomized controlled trials

Chronic Minocycline Treatment Exerts Antidepressant Effect, Inhibits Neuroinflammation, and Modulates Gut Microbiota in Mice

Effects of Aspirin in Rats With Ouabain Intracerebral Treatment-Possible Involvement of Inflammatory Modulation?

Minocycline in depression not responding to first-line therapy: A systematic review and meta-analysis

Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression

Multi-trial, aggregated, individual participant data mega-analysis of short-term antidepressant versus mood stabilizer monotherapy of bipolar type II major depressive episode

Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A): a randomised clinical trial of rosuvastatin and aspirin

Role of Minocycline as an Adjunct Neuroinflammatory Modulator in Treatment-Resistant Depression: A Systematic Review of Randomized Controlled Trials

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Verify the Efficacy and Safety of Ansofaxine (LY03005) for Major Depressive Disorder